IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
June 07, 2021 07:00 ET
|
IN8bio, Inc
Single-dose administration of IN8bio’s genetically modified gamma delta T-cells in lymphodepleted glioblastoma multiforme (GBM) patients was well tolerated No observed dose limiting toxicities...
IN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 20, 2021 16:00 ET
|
IN8bio, Inc
NEW YORK, May 20, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T...
IN8bio to Participate in Upcoming May Scientific Conferences
May 05, 2021 07:00 ET
|
IN8bio, Inc
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on discovery and development of innovative gamma-delta T cell...
IN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR
April 09, 2021 07:00 ET
|
IN8bio, Inc
DeltEx DRI CAR-T cells are gamma-delta T cells engineered with a Chlorotoxin CAR-T binding domain and a chemotherapy resistance gene, which enhances binding to tumor cells and survival of concomitant...
IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021
March 02, 2021 07:00 ET
|
IN8bio, Inc
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or the “Company”), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, announced...
IN8bio Appoints Patrick McCall as Chief Financial Officer
February 08, 2021 07:00 ET
|
IN8bio, Inc
NEW YORK, Feb. 08, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020
December 03, 2020 16:00 ET
|
IN8bio, Inc
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
IN8bio to Present at Upcoming December Investor Conferences
November 30, 2020 16:00 ET
|
IN8bio, Inc
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
IN8bio Appoints Alan S. Roemer as Chairman
October 07, 2020 07:00 ET
|
IN8bio, Inc
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
September 17, 2020 07:00 ET
|
IN8bio, Inc.
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...